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Abstract: HIV-infected patients develop abnormalities of glucose metabolism due to the 
virus and antiretroviral drugs. Spirulina and soybean are nutritional supplements that are 
cheap, accessible in our community and affect glucose metabolism. We carried out a 
randomized study to assess the effect of Spirulina platensis versus soybean as a food 
supplement on HIV/HAART-associated insulin resistance (IR) in 33 insulin-resistant   
HIV-infected patients. The study lasted for two months at the National Obesity Centre of 
Cameroon. Insulin resistance was measured using the short insulin tolerance test. Physical 
activity and diet did not change over the study duration. On-treatment analysis was used to 
analyze data. The Mann-Whitney U test, the Students T test and the Chi square test were 
used as appropriate. Curve gradients were analyzed using ANCOVA. Seventeen subjects 
were randomized to spirulina and 16 to soybean. Each received 19 g of supplement daily. 
The follow up rate was 65% vs. 100% for spirulina and soybean groups, respectively, and 
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both groups were comparable at baseline. After eight weeks, insulin sensitivity (IS) 
increased by 224.7% vs. 60% in the spirulina and soybean groups respectively (p < 0.001). 
One hundred per cent vs. 69% of subjects on spirulina versus soybean, respectively, 
improved their IS (p = 0.049) with a 1.45 (1.05–2.02) chance of improving insulin 
sensitivity on spirulina. This pilot study suggests that insulin sensitivity in HIV patients 
improves more when spirulina rather than soybean is used as a nutritional supplement. 
Trial registration: ClinicalTrials.gov identifier NCT01141777.  
Keywords: spirulina; soybean; insulin resistance; HIV; HAART 
 
1. Introduction 
Even though antiretroviral therapy (ART) has dramatically improved the health of people living 
with the human immunodeficiency virus (HIV) [1], the prospect of maintaining patients long term on 
highly active antiretroviral therapy (HAART) can be severely restricted by the development of serious 
long term metabolic complications. These abnormalities include insulin resistance (IR), dyslipidemia 
and changes in body fat distribution [2–8]. Insulin resistance leads to dyslipidemia [9] and precedes 
significant changes in body weight and fat redistribution in HAART-treated patients [10].  
Nutritional intervention [11–13] has been used successfully as a means of treating subjects with 
insulin resistance and diabetes either alone or in combination with physical activity [14] and/or drugs.  
Over the years, many dietary supplements have appeared in the market and have gained widespread 
use. The WHO projects that spirulina will become one of the most curative and prophylactic components 
of nutrition in the 21st century [15,16]. Preliminary studies suggest that it improves glycemic control, 
lowers cholesterol levels and reduces blood pressure [17,18] in diabetics. It is also cheap and easily 
available in our community and some researchers have even termed it a “superfood” [19].  
On the other hand, soybean has been used for several centuries by the Asians and is well known as 
a dietary supplement with beneficial effects on human health. It is also cheap and easily available in 
our community. Studies have shown differing effects on insulin sensitivity and glucose metabolism in 
animals and humans [20–22]. Data on the health effects of spirulina and especially soybeans in African 
populations are rare despite its wide consumption within this population. 
Given the fact that access to ART is increasing in Sub Saharan Africa, the prevalence of   
HAART-associated metabolic disorders is expected to rise in the coming years. There is therefore a need 
to research nutritional supplements that are cheap, easily available and can be used in the treatment 
and/or prevention of these metabolic abnormalities given the low purchasing power in this region.  
We therefore carried out this pilot study to evaluate the effect of these two supplements on 
HIV/HAART-associated insulin resistance (IR). 
2. Experimental Section  
The procedure used was in accordance with the guidelines of the Helsinki Declaration on human 
experimentation [23]. The study was approved by the National Ethics Committee of Cameroon Nutrients 2011, 3  
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(Authorization number 036/CNE/DNM/07). The purpose of the study was carefully explained and a 
written consent obtained from each subject before inclusion. 
2.1. Participants 
From March 2008 to January 2009, a total of 143 HIV-infected subjects were recruited at the Day 
Care Hospital of the Central Hospital of Yaounde. Subjects had been previously diagnosed as infected 
with HIV and followed up at the day care hospital.  
Adults confirmed as infected with HIV who agreed to participate in the study were included. All 
those with an acute intercurrent infection, on drugs that can modify the glucose or lipid profile other 
than HAART (steroids, insulin, etc.), actively taking tobacco, with renal failure (calculated creatinine 
clearance <60 mL/min), pregnant or known to be living with diabetes were excluded.  
2.2. Protocol 
2.2.1. Randomization, Treatment Allocation and Follow-Up 
Subjects were allocated to treatment groups by simple randomization. Pieces of paper were marked 
“spirulina” or “soya beans” and then sealed. These papers were put in a box in equal numbers. Each 
subject blindly selected a sealed piece of paper from the ballot box at random and then handed it to the 
person in charge of treatment allocation who then recorded the treatment group in a register that he 
kept confidential and then administered the appropriate treatment to the subject. At every point in time, 
the sealed papers were always in equal numbers in the box so as to give each subject a 50% chance of 
belonging to either group. When the first group was completed, all the remaining subjects were 
allocated to the second group. 
Spirulina was supplied by Antenna Technologies (Geneva, Switzerland) and soya beans were 
obtained from TANTY Ltd. (Yaounde, Cameroon). This spirulina was grown in the Republic of 
Equator and then packaged in Switzerland. 
Table 1. Composition of spirulina and soya beans used in the trial. 
 Spirulina  Soybean 
  Quantity per 100 g Quantity  per  100 g 
Protein  65 g  27 g 
Carbohydrates  15 g  58 g 
Lipids  6 g  8.6 g 
Calcium  1000 mg  106.3 mg 
Iron  180 mg  6.3 mg 
Magnesium 400  mg  - 
Minerals 7  mg  - 
Antenna Technologies is specialized in the growth, transformation and distribution of high quality 
spirulina while TANTY Ltd. is a Cameroonian company specialized in the growth, transformation and 
distribution of soya bean products. The composition of each supplement is shown above in Table 1. 
The supplements were given as powder (spirulina green, soya beans white-brown) and subjects took Nutrients 2011, 3  
 
 
715
19 g daily with meals and were also asked to continue their normal daily activities and diet without 
modification. To monitor these parameters, a questionnaire on diet and physical activity was 
established and administered to each subject before and at the end of the trial.  
Follow-up visits took place every two weeks after the onset of the trial. During these visits the 
supplements were replenished and compliance was evaluated. To do this, subjects were given a form 
which they had to fill every day after having taken the supplements. The number of intakes skipped 
every 2 weeks as recorded in these forms was noted down. 
2.2.2. Clinical Assessment 
Eligible subjects were randomized into two groups; spirulina and soya bean groups, and were each 
seen every two weeks for a total duration of 2 months. The duration of two months was chosen based 
on previous studies that showed significant effects of spirulina on glucose homeostasis within this 
period of time [17,18]. Subjects were asked to continue their diet and physical activity as usual.  
At study entry, patients had been fasting for at least eight hours overnight. The same operator noted 
the age and ART treatment regiment and duration of each eligible participant and evaluated their daily 
physical activity and diet using a quantitative questionnaire and assessed anthropometric data.  
Anthropometric measurements included weight, height, body mass index (BMI), waist circumference 
(WC) and total adiposity. Body height and weight (electronic weighing device, LAICA
®, Italy) were 
measured without shoes and in light clothing, respectively. BMI was measured as the ratio between the 
weight and the square of the height (kg/m
2). WC was measured as the circumference of the torso 
midway between the imaginary line that joins the twelfth rib to the iliac crest. Total adiposity was 
indirectly measured using a body fat monitor (Quantum III, RJL Systems, USA). Of the four 
electrodes emanating from the monitor, two were placed on the right hand and two on the right foot 
with the patient lying supine. Total body fat and lean body mass were calculated after introducing the 
resistance measured by the monitor into the NHANES III formulae [24]. All these measurements were 
repeated after 2 months of intervention. 
2.2.3. Biochemical Assays 
Insulin sensitivity was measured by the short insulin tolerance test (SITT) using the slope of blood 
glucose concentration from 3 to 15 min after a low dose intravenous bolus of rapid insulin. In 
particular, 0.1 IU/kg of rapid insulin was injected intravenously after the fasting blood glucose had 
been measured. Glycemia was then recorded every 3 min for a total duration of 15 min using the 
HEMOCUE 201+ glucose analyzer (Angelholm, Sweden). The faster the decline in glucose 
concentration, the more insulin-sensitive the subject is. The slope of the linear decline in plasma 
glucose, which is the insulin sensitivity index (KITT) was calculated by dividing ln 2 (0.693) by the 
plasma glucose half-life (50% from baseline) [25]. 
KITT = (0.693/t1/2) × 100 
where t1/2 represents the half-life of the decrease in plasma glucose. Given that this test is population 
dependent and that insulin sensitivity has a normal distribution, we defined as insulin-resistant, all 
subjects with insulin sensitivity index (KITT) within the first tertile of the insulin sensitivity Nutrients 2011, 3  
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distribution of the study population. Subjects with KITT in the last tertile of the insulin sensitivity 
distribution were considered as insulin-sensitive while all those with KITT in the middle tertile were 
considered as having intermediate insulin sensitivity.  
Five (5) mL of whole blood was collected from a peripheral vein for lipid assay. The blood was 
centrifuged at 4000 rev/min at 4 °C and the serum obtained was stored at −20 °C until analysis. Total 
cholesterol (TC) and triglycerides (TG) were measured by the LISA 380 Plus automat (Hycel 
Diagnostics, France). All these measurements were repeated eight weeks after onset of intervention.  
2.2.4. Outcome Measures 
Given that the main objective of this study was to determine the effect that spirulina has on insulin 
resistance associated with ART among HIV-infected people, the primary outcome was the percentage 
difference in change in insulin sensitivity between the two groups at the end of eight weeks of 
intervention. The secondary outcome was the percentage of subjects who improved insulin sensitivity 
by the end of the study, compared between the two groups. 
2.2.5. Sample Size 
The sample size for the study was calculated from an expected difference in change in insulin 
sensitivity of 20% between the two groups at the end of the study, using the mean insulin sensitivity, 
M, of a healthy Cameroonian population (M = 14.3 ± 2.2 mg/kg/min) [26]. Choosing α (two-sided) at 
0.05 and a statistical power of 80%, the minimum sample size was 10 IR subjects per group. The 
calculations are given below [27].  
The standardized difference,  
d = target difference/standard deviation 
d = 2.86/2.2 = 1.3 
For two equal groups, the sample size per group is given by the formula below [27]:  
n = (2/d
2) × Cp,power 
where  Cp,power  is a constant defined by the value chosen for the power and p value, available in 
statistical tables. With a power of 80% and a p value of 0.05, the constant is 7.9 [27]. 
Thus the sample size per group,  
n = (2/1.3
2) × 7.9  
n = 9.35 subjects 
This number was rounded up to a minimum of 10 insulin-resistant subjects per group. 
2.3. Statistical Methods 
Collected data was recorded on a preformed questionnaire which was computed and validated using 
the Epi Info software, Version 3.4.3. To ensure accuracy of data, all computerized entries were further 
checked against those on paper, item by item. Finally, data were exported to Microsoft Excel 2003, the Nutrients 2011, 3  
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Statistical Package for Social Sciences software, SPSS (Version 13.0) and Graphpad Prism (Version 5) 
for further analysis. 
Results are expressed as frequencies or mean and standard deviation. The Mann-Whitney U test and 
the Student’s T test were used to compare continuous data as appropriate. For categorical variables, the 
Chi square test was used. Gradients of curves were compared using analysis of covariance 
(ANCOVA). All p-values less than 0.05 were considered statistically significant for all analyses.  
3. Results and Discussion  
Of the 143 HIV-infected subjects assessed for insulin sensitivity, 49 were insulin resistant   
(KITT ≤ 1.620%/min), 47 had intermediate insulin sensitivity (1.620 < KITT ≤ 1.683) and 47 were 
insulin sensitive (KITT > 1.683). Of the 49 subjects eligible for the trial, 3 did not meet inclusion 
criteria while 13 refused to participate. Seventeen were therefore randomized to spirulina and 16 to the 
soybean group. Two subjects were discontinued treatment in the spirulina group due to acute 
intercurrent infection, 2 withdrew their consent while 2 loses to follow up were registered in the 
spirulina group giving an overall follow up rate of 82% (Figure 1). 
Figure 1. Participant flow in the course of the study. 
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Excluded from analysis (n = 6) 
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(n = 17) 
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Physical activity and diet did not change over the study duration. The mean number of days during 
which the supplement was taken was significantly lower for spirulina than for soya beans (44.8 ± 19.1 
versus 59.4 ± 1.5 days, p = 0.005). This could be explained by the fact that all subjects on spirulina as 
opposed to none on soya bean complained about the taste, saying that it was not palatable. This 
difference in taste could account for the significantly lower compliance demonstrated in the spirulina 
group and partly for the number of losses to follow up observed (65% follow up rate in spirulina 
versus 100% follow up rate in soya beans). But despite the loss to follow up and lower number of days 
of intake registered in the spirulina group (45 days), the effect on insulin sensitivity was significant. 
This mean duration of 45 days is similar to the duration of spirulina intake in a Mexican study done to 
assess the impact of spirulina on blood pressure [18]. However, we recommend that future studies 
should use spirulina forms which are more palatable to improve compliance. 
After randomisation, the spirulina and soya bean groups were comparable for all anthropometric 
and biological parameters that were measured (Table 2).  
Table 2. Baseline characteristics of subjects. 
Characteristics Spirulina  (n = 17) Soya  bean  (n = 16)  p value
Demographic and Clinical 
Sex, n  
Men  4   3  
0.74 
Women  13   13  
Treatment regiment 
ZDV+ 12  12 
0.95  D4T+ 4  3 
Treatment naive  1  1 
Age, mean (SD), years  36 (11) 39  (7)  0.45 
HAART duration, mean (SD), months  22 (14)  27 (17)  0.23 
BMI, mean (SD), kg/m
2 23.8  (3.2) 24.7  (2.8)  0.40 
Systolic BP, mean (SD), mmHg  127 (17)  121 (11)  0.20 
Diastolic BP, mean (SD), mmHg  78 (10)  80 (7)  0.63 
Waist Circumference, mean (SD), cm  82.2 (9.1) 82.3  (7.3)  0.98 
Fat-free mass, mean (SD), kg  38.2 (11.5)  37.1 (10.9)  0.78 
Percent Body Fat, mean (SD), %  39.1 (17.4)  41.6 (16.3) 0.45 
Biological 
CD4 count, median (Q1–Q3), µL  277 (75.5–472.3) 226  (112–402) 1.0 
Total cholesterol, mean (SD), g/L  1.7 (0.49) 1.8  (0.43) 0.54 
Triglycerides, mean (SD), g/L  0.7 (0.53) 0.6  (0.28) 0.77 
Abbreviations: n, number of subjects; SD, Standard deviation; HAART, Highly active antiretroviral 
therapy; BMI, Body mass index; BP, Blood pressure; ZDV+, Zidovudine present; D4T+, Stavudine 
present; Q1–Q3, 25th–75th percentile. 
The rate of blood glucose decline during the SITT, which reflects insulin sensitivity (Figure 2), was 
also comparable between the two groups (−0.81%/min vs. −1.05%/min, p = 0.29) at baseline. 
After 2 months of intervention, the rate of blood glucose decrease during SITT was significantly 
greater in the spirulina group (−2.63%/min vs. −1.68%/min, p = 0.005) compared to the soyabeans 
group (Figure 3).  
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In our subjects, the fat-free mass of subjects on spirulina also increased while that of subjects on 
soybean decreased (Table 3). The muscle is a major component of the fat-free mass and is responsible 
for 80% to 95% of glucose uptake at high insulin concentrations [30]. Therefore, glucose disposal 
following insulin injection could be better in the spirulina group with a higher fat-free mass.  
Soybean has controversial effects on glucose metabolism. Most animal studies have shown an 
improvement in insulin sensitivity and other parameters of glucose homeostasis [22,31–34]. However, 
one recently published study showed that in rats recovering from early life malnutrition that were fed 
on a soybean diet, there was an alteration in the insulin signaling pathway, leading to an increase in 
insulin resistance [35]. In humans, early studies done in diabetics registered an improvement in 
glycemic control [36], but recently published studies have not shown any beneficial effects on indices 
of glucose homeostasis [21,37]. These different results could be due to different study design, different 
daily intake and forms (fermented or not) of soybean protein and different study duration. In our study, 
insulin sensitivity improved within the soybean group (60% increase from baseline) but was 
significantly lower than the improvement observed in the spirulina group (167.7% difference between 
the two groups, p < 0.001). This indicates that, regardless of the true effect of soybean on glucose 
homeostasis in humans, spirulina seems to be superior to soybean in correcting HIV/HAART-associated 
insulin resistance. 
No significant difference was noted in other anthropometric and the following biological parameters 
(CD4 count, TC and TG) measured between the two groups even though a trend of lower fat-free mass 
and TC were detected in the spirulina group after eight weeks (34.5 kg ± 11.1 vs. 36.9 kg ± 10.9,  
p = 0.59 and 2.38 g/L ± 0.67 vs. 2.65 g/L ± 0.67, p = 0.32, respectively). 
In both groups, the fasting glycemia, TC and TG levels increased but this increase was greater in 
the soybean group than in the spirulina group. This suggests that spirulina seems to better retard the 
aggravation of HAART-induced hyperglycaemia and dyslipidaemia as opposed to soybean, as shown 
by the lower increases in FBG, TC and TG levels.  
Table 3. Change of other characteristics from baseline. 
  Spirulina (n = 11) Soya  bean  (n = 16) 
Waist Circumference, mean (SD), cm  −0.40 (3.16)  +0.01 (2.34) 
Total Body Fat, mean (SD), kg  +0.36 (4.52)  +0.38 (3.30) 
Fat-Free Mass, mean (SD), kg  +0.35 (2.01)  −1.59 (1.57) 
Fasting glycemia, mean (SD), g/L  +1.3 (0.9)  +1.8 (2.1) 
Total cholesterol, mean (SD), g/L  +0.63 (0.53)  +0.87 (0.79) 
Triglycerides, mean (SD), g/L  +0.48 (0.52)  +0.61 (0.70) 
Abbreviation: n, number of subjects; SD, Standard deviation. 
Although in this pilot study, spirulina intake was associated with a better improvement in insulin 
sensitivity than soybean intake, our results are limited by the small sample size and losses to follow up 
in the spirulina group (35%). Also, even though the groups were well balanced for factors that can 
influence insulin sensitivity at baseline like age, sex, type and duration of HAART exposure, BMI and 
WC, other factors like the presence or absence of hepatic steatosis and lipodystrophy were not 
investigated. Nevertheless, predictors for lipodystrophy (sex, type and duration of exposure to 
HAART) were comparable between the groups, indicating that lipodystrophy was also evenly Nutrients 2011, 3  
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distributed at baseline. Consequently, further studies that take these limitations into account are 
required to replicate our results. 
4. Conclusions  
In conclusion, spirulina supplementation in HIV patients may play a more beneficial role than 
soybean intake in improving on HIV/HAART associated insulin resistance. Further studies, involving 
more subjects and for a longer duration, are required to replicate these results and uncover the 
underlying mechanisms involved. 
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